Copaxone may offer protection from axonal injury: "Clinical research data, published in the journal Multiple Sclerosis, provided evidence that Copaxone ( Glatiramer ) may offer protection from axonal injury and induced neuronal metabolic recovery in patients with relapsing remitting multiple sclerosis ( RRMS ).
In a pilot study of 18 RRMS patients using brain imaging techniques, Copaxone was found to produce significant increases in n-acetylaspartate/creatine ( NAA/Cr ) ratio, an indicator of neuron and axon integrity, compared to four untreated control patients after one year of treatment............"